Literature DB >> 30455251

Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity.

Leixiang Yang1, Tanjing Song1, Qian Cheng1, Lihong Chen1, Jiandong Chen2.   

Abstract

Missense p53 mutants often accumulate in tumors and drive progression through gain of function. MDM2 efficiently degrades wild-type p53 but fails to degrade mutant p53 in tumor cells. Previous studies revealed that mutant p53 inhibits MDM2 autoubiquitination, suggesting that the interaction inhibits MDM2 E3 activity. Recent work showed that MDM2 E3 activity is stimulated by intramolecular interaction between the RING and acidic domains. Here, we show that in the mutant p53-MDM2 complex, the mutant p53 core domain binds to the MDM2 acidic domain with significantly higher avidity than wild-type p53. The mutant p53-MDM2 complex is deficient in catalyzing ubiquitin release from the activated E2 conjugating enzyme. An MDM2 construct with extra copies of the acidic domain is resistant to inhibition by mutant p53 and efficiently promotes mutant p53 ubiquitination and degradation. The results suggest that mutant p53 interferes with the intramolecular autoactivation mechanism of MDM2, contributing to reduced ubiquitination and increased accumulation in tumor cells.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  E3 ligase; MDM2; RING domain; acidic domain; conformation; mutant p53; ubiquitination

Mesh:

Substances:

Year:  2019        PMID: 30455251      PMCID: PMC6362316          DOI: 10.1128/MCB.00375-18

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  54 in total

1.  DNA damage induces MDMX nuclear translocation by p53-dependent and -independent mechanisms.

Authors:  Changgong Li; Lihong Chen; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

2.  Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein.

Authors:  Lindsay Burch; Harumi Shimizu; Amanda Smith; Cam Patterson; Ted R Hupp
Journal:  J Mol Biol       Date:  2004-03-12       Impact factor: 5.469

3.  Ubiquitination and degradation of mutant p53.

Authors:  Natalia Lukashchuk; Karen H Vousden
Journal:  Mol Cell Biol       Date:  2007-10-01       Impact factor: 4.272

4.  Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions.

Authors:  D Walerych; M B Olszewski; M Gutkowska; A Helwak; M Zylicz; A Zylicz
Journal:  Oncogene       Date:  2009-09-14       Impact factor: 9.867

5.  Mapping of the p53 and mdm-2 interaction domains.

Authors:  J Chen; V Marechal; A J Levine
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

6.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.

Authors:  R Honda; H Tanaka; H Yasuda
Journal:  FEBS Lett       Date:  1997-12-22       Impact factor: 4.124

7.  Autoinhibition of MDMX by intramolecular p53 mimicry.

Authors:  Lihong Chen; Wade Borcherds; Shaofang Wu; Andreas Becker; Ernst Schonbrunn; Gary W Daughdrill; Jiandong Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

8.  ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage.

Authors:  R Maya; M Balass; S T Kim; D Shkedy; J F Leal; O Shifman; M Moas; T Buschmann; Z Ronai; Y Shiloh; M B Kastan; E Katzir; M Oren
Journal:  Genes Dev       Date:  2001-05-01       Impact factor: 11.361

Review 9.  p53 and its mutants in tumor cell migration and invasion.

Authors:  Patricia A J Muller; Karen H Vousden; Jim C Norman
Journal:  J Cell Biol       Date:  2011-01-24       Impact factor: 10.539

10.  Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8.

Authors:  W Yan; S Liu; E Xu; J Zhang; Y Zhang; X Chen; X Chen
Journal:  Oncogene       Date:  2012-03-05       Impact factor: 9.867

View more
  6 in total

Review 1.  Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up.

Authors:  Yanling Wang; Qijun Li; Jing Wang; Mengting Tong; Haibo Xing; Yanan Xue; Hongming Pan; Changxing Huang; Da Li
Journal:  Med Oncol       Date:  2019-10-29       Impact factor: 3.064

2.  MDM2-C Functions as an E3 Ubiquitin Ligase.

Authors:  Jun Yeob Kim; Rusia Lee; Gu Xiao; Dominique Forbes; Jill Bargonetti
Journal:  Cancer Manag Res       Date:  2020-08-24       Impact factor: 3.989

Review 3.  Targeting Post-Translational Regulation of p53 in Colorectal Cancer by Exploiting Vulnerabilities in the p53-MDM2 Axis.

Authors:  Chunwei W Lai; Cindy Xie; Jean-Pierre Raufman; Guofeng Xie
Journal:  Cancers (Basel)       Date:  2022-01-03       Impact factor: 6.639

Review 4.  It's Getting Complicated-A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy.

Authors:  Che-Pei Kung; Jason D Weber
Journal:  Front Cell Dev Biol       Date:  2022-01-26

Review 5.  Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention.

Authors:  Chee Wai Fhu; Azhar Ali
Journal:  Cancers (Basel)       Date:  2021-03-25       Impact factor: 6.639

Review 6.  Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System.

Authors:  Ruqaia Abbas; Sarit Larisch
Journal:  Cells       Date:  2021-12-08       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.